Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.77 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.61 |
| ▸ | FAP | Q12884 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30065223 | 1.00 | DPP4 (0.77) | DPP4CYP3A4CYP2D6CYP1A2DPP8 | |
| Water SCHEMBL4313660 | 0.99 | DPP4 (0.79) | DPP4CYP3A4CYP2D6CYP1A2DPP8 | |
| Water SCHEMBL4313664 | 0.99 | DPP4 (0.79) | DPP4CYP3A4CYP2D6CYP1A2DPP8 | |
| Water SCHEMBL4313663 | 0.99 | DPP4 (0.79) | DPP4CYP3A4CYP2D6CYP1A2DPP8 | |
| Hydrochloric Acid SCHEMBL3894480 | 0.99 | DPP4 (0.79) | DPP4CYP3A4CYP2D6CYP1A2DPP8 | |
| Hydrochloric Acid SCHEMBL919148 | 0.98 | DPP4 (0.80) | DPP4CYP3A4CYP2D6CYP1A2DPP8 | |
| Hydrochloric Acid SCHEMBL919150 | 0.98 | DPP4 (0.80) | DPP4CYP3A4CYP2D6CYP1A2DPP8 | |
| SCHEMBL14648441 | 0.90 | DPP4 (0.68) | DPP4CYP3A4CYP2D6CYP1A2DPP8 | |
| SCHEMBL13647295 | 0.89 | DPP4 (0.67) | DPP4CYP3A4CYP2D6CYP1A2DPP8 | |
| SCHEMBL13647358 | 0.88 | DPP4 (0.65) | DPP4CYP3A4CYP2D6CYP1A2DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312456-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2025-10-09 | — | — | US | claimed |
| US-20220323434-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2022-10-13 | — | — | US | claimed |
| CN-112656945-A | Treatment of diabetes in patients unsuited for metformin therapy | 勃林格殷格翰国际有限公司 | 2021-04-16 | — | — | CN | claimed |
| US-20210093633-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2021-04-01 | — | — | US | claimed |
| US-10894787-B2 | Modulators of the GPR119 receptor and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2021-01-19 | — | — | US | claimed |
| EP-3626238-A1 | DPP-4 INHIBITORS FOR USE FOR THE TREATMENT OF WOUND HEALING IN DIABETIC PATIENTS | Boehringer Ingelheim International GmbH (DE) | 2020-03-25 | — | — | EP | claimed |
| US-20190105321-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2019-04-11 | — | — | US | claimed |
| EP-3323818-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2018-05-23 | — | — | EP | claimed |
| US-20160206620-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-07-21 | — | — | US | claimed |
| US-8853156-B2 | Treatment for diabetes in patients inappropriate for metformin therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-07 | — | — | US | claimed |
| JP-2012500190-A | — | — | 2012-01-05 | — | — | JP | claimed |
| JP-2011529945-A | — | — | 2011-12-15 | — | — | JP | claimed |
| US-20110263493-A1 | Treatment for diabetes in patients inappropriate for metformin therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | claimed |
| WO-2011127051-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | WO | claimed |
| US-20110190322-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | US | claimed |
| EP-2326326-A2 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2011-06-01 | — | — | EP | claimed |
| EP-2323650-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | Boehringer Ingelheim International GmbH (DE) | 2011-05-25 | — | — | EP | claimed |
| WO-2011005929-A1 | PIPERIDINE DERIVATIVE AND ITS USE FOR THE TREATMENT OF DIABETS AND OBESITY | ARENA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | claimed |
| WO-2010018217-A2 | ORGANIC COMPOUNDS FOR WOUND HEALING | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | WO | claimed |
| WO-2010015664-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093633-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | DPP4 1/4885CYP3A4 78/4885CYP2D6 92/4885 |
| US-20160206620-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | DPP4, DPP7, DPP3 | DPP4 1/4885CYP3A4 3420/4885CYP2D6 3571/4885 |
| US-20250312456-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | DPP4 1/4885CYP3A4 78/4885CYP2D6 92/4885 |
| US-20110263493-A1 | Treatment for diabetes in patients inappropriate for metformin therapy | DPP4, DPP3, DPP7 | DPP4 1/4885CYP3A4 78/4885CYP2D6 92/4885 |
| US-20110190322-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | DPP4, DPP7, DPP3 | DPP4 1/4885CYP3A4 3420/4885CYP2D6 3571/4885 |
| US-20220323434-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | DPP4 1/4885CYP3A4 78/4885CYP2D6 92/4885 |
| US-10894787-B2 | Modulators of the GPR119 receptor and the treatment of disorders related thereto | GPR119, GLP1R, DPP9 | DPP4 5/4885CYP3A4 1716/4885CYP2D6 2317/4885 |
| US-20190105321-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | DPP4 1/4885CYP3A4 78/4885CYP2D6 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.